Common questions about Versican Plus L4 (FAQ)
Q: How quickly after administration does Versican Plus L4 start working?
Official regulatory documents indicate that the onset of protective immunity is achieved four weeks following the completion of the primary two-dose course. This is the period established in studies for the immune system to generate a protective response against the serovars.
Q: How long does the protection from Versican Plus L4 last?
Studies and official product information confirm that the duration of protective immunity against all components is established to be at least one year. The official regulatory regimen specifies maintenance through a single annual re-vaccination dose.
Q: What happens if the second dose of Versican Plus L4 is delayed?
The official product information defines the primary course as two doses administered specifically 3–4 weeks apart. The regulatory text does not provide explicit public instructions or guidance for handling a delay outside of this defined period for the primary course.
Q: If a dog misses a booster, what is the usual re-vaccination protocol for Versican Plus L4?
The standard usage sections of the official regulatory documentation do not contain explicit instructions for the protocol to follow if an annual re-vaccination dose is missed. Specific protocols for addressing a missed booster are not publicly defined in these documents.
Q: Can Versican Plus L4 be used in pregnant dogs?
The official documents state the product is authorized for use during the second and third stages of pregnancy. However, safety information for the early stage of pregnancy and during lactation has not been investigated, and therefore its use is not established during those specific times.
Q: How is the efficacy of Versican Plus L4 generally measured in studies?
Efficacy is established through regulatory studies that measure the prevention of clinical signs, infection, and urinary excretion associated with the serovars. Antibody levels against the active components are specifically measured using the Antibody Micro Agglutination-Lytic Reaction (ALR) titer.
Q: Are there any long-term side effects associated with Versican Plus L4?
The regulatory safety profile reports all adverse reactions identified during trials, classified by frequency (Common, Rare, Very Rare). The profile does not contain a separate classification for side effects specific to a long-term period, as all identified events are listed within these classifications.
Q: What should be watched for after a dog receives Versican Plus L4?
The most frequently reported reaction is a common, transient swelling at the injection site that typically resolves within 14 days. Less common reactions noted in the safety profile include signs of decreased activity and decreased appetite.
Q: Is Versican Plus L4 safe for small breed dogs?
The regulatory documentation lists the target species as all dogs and specifies a fixed 1 ml dose volume for all animals. There are no breed-specific safety restrictions or warnings mentioned in the official profile.
Q: Is Versican Plus L4 safe for dogs with a history of allergic reactions?
The official profile notes that rare hypersensitivity reactions are possible and may become life-threatening. While contraindications are generally listed as 'None,' the product is intended for use only in healthy animals.
Q: Why is Leptospirosis included in this vaccine combination?
The vaccine is licensed to induce active immunity against the four specific Leptospira serovars it contains. This is done to prevent clinical signs, infection, and urinary excretion associated with these bacterial diseases.
Q: What other common veterinary products are known to interact with Versican Plus L4?
Official documents only specify compatibility when mixed with certain other specific Zoetis vaccines (Versican Plus DHPPi, Versican Plus Pi, Versiguard Rabies). For all other veterinary medicinal products, no information is available in the regulatory profile regarding the safety and efficacy of co-administration.
Q: What kind of research has been done on the duration of immunity for Versican Plus L4?
Research was conducted to establish the duration of immunity against the specified serovars. The regulatory outcome of these studies is the claim of protection lasting for at least one year following the completion of the primary vaccination course.
Q: What were the results of the key studies for Versican Plus L4?
The results supporting the product’s licensing demonstrate the ability to prevent clinical signs and reduce infection and urinary excretion caused by the four specified Leptospira serovars.
Q: Where can I find the official regulatory document for Versican Plus L4?
The official public regulatory documents, such as the Summary of Product Characteristics (SmPC) and the European Public Assessment Report (EPAR), are available through the government websites of the European Medicines Agency (EMA) and national regulatory bodies like the UK’s Veterinary Medicines Directorate (VMD).
Q: Does Versican Plus L4 offer protection against other diseases not listed in its description?
The product is licensed solely for the active immunization against the four specific Leptospira serovars listed in its product description. Its indications do not extend to protection against unlisted diseases.
Q: Is it typical for a dog to have a decreased appetite after receiving Versican Plus L4?
A decreased appetite (anorexia) is documented in the safety profile as a rare adverse reaction. This means it has been reported in a small number of treated animals, specifically 1 to 10 animals per 10,000 treated.
Q: How can I tell the difference between a normal reaction and a serious side effect from Versican Plus L4?
The most frequently reported effect is a common, localized, transient swelling at the injection site that typically resolves within 14 days. Reactions classified as rare or very rare, such as severe hypersensitivity or signs of immune-mediated conditions, are considered more serious events.
Q: Is Versican Plus L4 a core or non-core vaccination?
Regulatory documents classify the product as an inactivated bacterial vaccine intended for the active immunization against the four specific Leptospira serovars listed in its composition.
Q: Does the efficacy of Versican Plus L4 depend on the dog's weight?
The official dosage and administration instructions establish a fixed dose of 1 ml for every application, regardless of the individual dog's weight or size.
Q: Why is the L4 part of the name used?
The designation L4 in the product name signifies that the product's composition includes four distinct inactivated Leptospira serovars, offering an expanded spectrum of coverage.
Q: What is the full list of ingredients in Versican Plus L4?
The active components include the four inactivated Leptospira serovars and the adjuvant, Aluminium hydroxide. The full list of excipients (inactive ingredients) is provided in the official regulatory documents and includes common components such as Trometamol, Sucrose, Dextran 70, various salts, and Water for injections.
Q: Are there any breed-specific concerns mentioned in the research for Versican Plus L4?
The regulatory documents list the target species as all dogs and do not contain any breed-specific restrictions or concerns regarding the use of this product.
Q: Can Versican Plus L4 be given to dogs who are already taking antibiotics?
The regulatory text contains a general warning that the animal's immune response may be compromised by a variety of factors, including concurrent medicinal therapy. The product is intended for use only in healthy animals.
Q: Are there any official reports on adverse events related to Versican Plus L4?
Yes, the official regulatory documentation outlines the requirement for continuous safety monitoring through a formal pharmacovigilance system. Adverse events are reported to the national system and the marketing authorization holder for ongoing safety assessment.
Q: Does Versican Plus L4 protect against all types of Leptospirosis?
The protection offered by the product is specific to the four inactivated Leptospira serovars listed in its composition (Icterohaemorrhagiae, Canicola, Grippotyphosa, and Australis serovar Bratislava).
Q: How is the safety of Versican Plus L4 tracked after it has been licensed?
Safety is tracked after licensing through a formal pharmacovigilance system. This system requires the continuous reporting of adverse events to the national regulatory reporting system for ongoing safety monitoring and evaluation.
